saltar al contingut principal
saltar al peu de pàgina

COL·LABORA El Meu Clínic

Pere Gascón

gascon@clinic.cat

Publicacions destacades

Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppres

Autors:
Blackwell, K.; Gascon, P.; Krendyukov, A.; Gattu, S.; Li, Y.;

Harbeck, N.;.

Referència: ANNALS OF ONCOLOGY.
Fatigue- and health-related quality-of-life in anemic patients with lymphoma or multiple myeloma

Autors:
Gascon, Pere; Arranz, Reyes; Bargay, Joan; Ramos, Fernando;;

Referència: SUPPORTIVE CARE IN CANCER.
MONITOR-GCSF DLBCL subanalysis: Treatment patterns/outcomes with biosimilar filgrastim for chemotherapy-induced/febrile neutropenia prophylaxis

Autors:
Gascon, Pere; Krendyukov, Andriy; Hoebel, Nadja; Aapro, Matti;;

Referència: EUROPEAN JOURNAL OF HAEMATOLOGY.
Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies

Autors:
Harbeck N.; Gascón P.; Krendyukov A.; Hoebel N.; Gattu S.;

Blackwell K..

Referència: ONCOLOGIST.
Histamine receptor 1 inhibition enhances antitumor therapeutic responses through extracellular signal-regulated kinase (ERK) activation in breast cancer

Autors:
Fernández-Nogueira P.; Noguera-Castells A.; Fuster G.; Recalde-Percaz L.; Moragas N.;

(...)

Carbó N.; Almendro V.; Gascón P.; Bragado P.; Mancino M..

Referència: CANCER LETTERS.

Projectes destacats

Inflammation and breast cancer: neuronal influence and pro-inflammatory neuropeptides in the tumoral progression through the modulation of the stem cell phenotype.

Finançador: INSTITUTE OF HEALTH CARLOS III. FISS PI12/01706

Durada: 01/01/2013
Mechanisms of transactivation of ErbB family members in breast cancer: a role for tachykinins and the neoneurogenesis.

Finançador: INSTITUTE OF HEALTH CARLOS III. FISS PI080022

Durada: 01/01/2009
Effect of integrins and neurokinins in cancer development”

Finançador: INSTITUTE OF HEALTH CARLOS III. FISS PI041353

Durada: 01/01/2004